## SUBSTITUTE FOR HOUSE BILL NO. 6073

A bill to amend 1975 PA 228, entitled "Single business tax act,"

(MCL 208.1 to 208.145) by adding section 39f.

## THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1 SEC. 39F. (1) FOR TAX YEARS THAT BEGIN AFTER DECEMBER 31,
- 2 2002, AN ELIGIBLE TAXPAYER MAY CLAIM A CREDIT AGAINST THE TAX
- 3 IMPOSED BY THIS ACT EQUAL TO 6-1/2% OF THE EXCESS OF QUALIFIED
- 4 RESEARCH EXPENSES PAID IN THE TAX YEAR THAT RELATE TO THE ELIGI-
- 5 BLE TAXPAYER'S PHARMACEUTICAL BASED BUSINESS ACTIVITY IN THIS
- 6 STATE OVER THE AVERAGE QUALIFIED RESEARCH EXPENSES THAT RELATE TO
- 7 THE ELIGIBLE TAXPAYER'S PHARMACEUTICAL BASED BUSINESS ACTIVITY IN
- 8 THIS STATE PAID DURING THE 3 IMMEDIATELY PRECEDING TAX YEARS.
- 9 (2) THE AMOUNT OF A CREDIT FOR ANY TAX YEAR UNDER SUBSECTION
- 10 (1) SHALL NOT EXCEED 200% OF THE ELIGIBLE TAXPAYER'S AVERAGE
- 11 QUALIFIED RESEARCH EXPENSES THAT RELATE TO THE TAXPAYER'S

## HB6073, As Passed House, September 24, 2002

House Bill No. 6073

2

- 1 PHARMACEUTICAL BASED BUSINESS ACTIVITY IN THIS STATE FOR THE 3
- 2 IMMEDIATELY PRECEDING TAX YEARS.
- 3 (3) IF THE CREDIT ALLOWED UNDER THIS SECTION FOR THE TAX
- 4 YEAR AND ANY UNUSED CARRYFORWARD OF THE CREDIT ALLOWED UNDER THIS
- 5 SECTION EXCEED THE TAX LIABILITY OF THE TAXPAYER FOR THE TAX
- 6 YEAR, THE EXCESS SHALL NOT BE REFUNDED BUT MAY BE CARRIED FORWARD
- 7 AS AN OFFSET TO THE TAX LIABILITY IN SUBSEQUENT TAX YEARS FOR 7
- 8 TAX YEARS OR UNTIL THE EXCESS CREDIT IS USED UP, WHICHEVER OCCURS
- 9 FIRST.
- 10 (4) A MEMBER OF AN AFFILIATED GROUP AS DEFINED IN THIS ACT,
- 11 A CONTROLLED GROUP OF CORPORATIONS AS DEFINED IN SECTION 1563 OF
- 12 THE INTERNAL REVENUE CODE AND FURTHER DESCRIBED IN 26 C.F.R.
- 1.414(b)-1 AND 1.414(c)-1 TO 1.414(c)-5, OR AN ENTITY UNDER
- 14 COMMON CONTROL AS DEFINED BY THE INTERNAL REVENUE CODE SHALL
- 15 DETERMINE THE CREDIT ALLOWED UNDER THIS SECTION ON A CONSOLIDATED
- 16 BASIS.
- 17 (5) AN ELIGIBLE TAXPAYER MAY ASSIGN ALL OR A PORTION OF A
- 18 CREDIT ALLOWED UNDER THIS SECTION. A CREDIT ASSIGNMENT UNDER
- 19 THIS SUBSECTION IS IRREVOCABLE AND SHALL BE MADE IN THE TAX YEAR
- 20 IN WHICH QUALIFIED RESEARCH EXPENSES ARE PAID. AN ELIGIBLE TAX-
- 21 PAYER MAY CLAIM A PORTION OF THE CREDIT AND ASSIGN A PORTION OF
- 22 THE REMAINING CREDIT AMOUNT. HOWEVER, THE ELIGIBLE TAXPAYER
- 23 SHALL NOT ASSIGN IN ANY TAX YEAR MORE THAN 40% OF THE TOTAL
- 24 AMOUNT OF THE CREDIT ALLOWED FOR THAT YEAR. IF THE ELIGIBLE TAX-
- 25 PAYER BOTH CLAIMS AND ASSIGNS PORTIONS OF THE CREDIT, THE ELIGI-
- 26 BLE TAXPAYER SHALL CLAIM THE PORTION IT CLAIMS IN THE TAX YEAR IN
- 27 WHICH THE QUALIFIED RESEARCH EXPENSES ARE PAID. AN ASSIGNEE

## HB6073, As Passed House, September 24, 2002

House Bill No. 6073

- 1 SHALL NOT SUBSEQUENTLY ASSIGN A CREDIT OR ANY PORTION OF A CREDIT
- ASSIGNED UNDER THIS SUBSECTION. THE CREDIT ASSIGNMENT UNDER THIS 2
- 3 SUBSECTION SHALL BE MADE ON A FORM PRESCRIBED BY THE DEPARTMENT.
- THE ELIGIBLE TAXPAYER SHALL SEND A COPY OF THE COMPLETED ASSIGN-4
- MENT FORM TO THE DEPARTMENT IN THE TAX YEAR IN WHICH THE ASSIGN-5
- 6 MENT IS MADE. THE ASSIGNEE SHALL ATTACH A COPY OF THE COMPLETED
- 7 ASSIGNMENT FORM TO ITS ANNUAL RETURN REQUIRED UNDER THIS ACT, FOR
- 8 THE TAX YEAR IN WHICH THE ASSIGNMENT IS MADE AND THE ASSIGNEE
- FIRST CLAIMS A CREDIT, WHICH SHALL BE THE SAME TAX YEAR. 9
- 10 (6) THE TOTAL OF ALL CREDITS ALLOWED UNDER THIS SECTION
- 11 SHALL NOT EXCEED \$10,000,000.00 FOR ANY 1 TAX YEAR.
- 12 (7) AS USED IN THIS SECTION:
- 13 (A) "ELIGIBLE TAXPAYER" MEANS A COMPANY THAT MEETS ALL OF
- 14 THE FOLLOWING CRITERIA WITHIN 18 MONTHS AFTER THE EFFECTIVE DATE
- 15 OF THE AMENDATORY ACT THAT ADDED THIS SECTION:
- 16 (i) IS ENGAGED PRIMARILY IN MANUFACTURING, RESEARCH AND
- DEVELOPMENT, AND SALE OF PHARMACEUTICALS. 17
- 18 (ii) HAS NOT LESS THAN 8,500 EMPLOYEES LOCATED IN THIS
- 19 STATE. THE PRIMARY PLACES OF EMPLOYMENT FOR ALL THE EMPLOYEES
- 20 REOUIRED UNDER THIS SUBPARAGRAPH SHALL BE LOCATED WITHIN A
- 21 100-MILE RADIUS OF EACH OTHER.
- (iii) OF THE TOTAL NUMBER OF EMPLOYEES LOCATED IN THIS 22
- 23 STATE, HAS NOT LESS THAN 5,000 ENGAGED PRIMARILY IN RESEARCH AND
- 24 DEVELOPMENT OF PHARMACEUTICALS.
- 25 (B) "QUALIFIED RESEARCH EXPENSES" MEANS THAT TERM AS DEFINED
- 26 IN SECTION 41 OF THE INTERNAL REVENUE CODE.